ADAG vs ZLAB vs BCAB vs JPM vs IMVT

For growth investors, Zai Lab Limited (ZLAB) is the stronger pick with 15.

3% revenue growth year-over-year, versus -99. 4% for Adagene Inc. (ADAG). JPMorgan Chase & Co. (JPM) offers the better valuation at 16. 0x trailing P/E (14. 4x forward), making it the more compelling value choice. Analysts rate Adagene Inc. (ADAG) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Immunovant, Inc.

(IMVT) delivered a total return of +213. 0%, compared to -99. 8% for BioAtla, Inc. (BCAB). Over 10 years, the gap is even starker: JPM returned +465. 8% versus BCAB's -99. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), BioAtla, Inc.

(BCAB) is the lower-risk stock at 0. 25β versus Immunovant, Inc. 's 1. 66β — meaning IMVT is approximately 552% more volatile than BCAB relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Zai Lab Limited (ZLAB) is pulling ahead at 15.

3% versus -99. 4% for Adagene Inc. (ADAG). On earnings-per-share growth, the picture is similar: Zai Lab Limited grew EPS 38. 5% year-over-year, compared to -75. 9% for Adagene Inc.. Over a 3-year CAGR, ZLAB leads at 28. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

JPMorgan Chase & Co.

(JPM) is the more profitable company, earning 20. 4% net margin versus -323. 9% for Adagene Inc. — meaning it keeps 20. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 26. 0% versus -348. 4% for ADAG. At the gross margin level — before operating expenses — BCAB leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for BCAB: 6376.

7% to $250. 00.

In this comparison, JPM (1.

9% yield) pays a dividend. ADAG, ZLAB, BCAB, IMVT do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, JPMorgan Chase & Co.

(JPM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 94), 1. 9% yield, +465. 8% 10Y return). Immunovant, Inc. (IMVT) carries a higher beta of 1. 66 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (JPM: +465. 8%, IMVT: +237. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ADAG (Healthcare) and ZLAB (Healthcare) and BCAB (Healthcare) and JPM (Financial Services) and IMVT (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ADAG is a small-cap quality compounder stock; ZLAB is a small-cap high-growth stock; BCAB is a small-cap quality compounder stock; JPM is a large-cap deep-value stock; IMVT is a small-cap quality compounder stock. JPM pays a dividend while ADAG, ZLAB, BCAB, IMVT do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.